Therefore, they are particularly meaningful for the future design of a CK1α isoform-specific inhibitor that could be tested in a therapeutic perspective against MM plasma cellular disease and the adverse effects of MM-associated bone disease. This evidence concerns the gene CSNK1A1 and Miyoshi myopathy.